BRPI0906261A2 - "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" - Google Patents

"métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"

Info

Publication number
BRPI0906261A2
BRPI0906261A2 BRPI0906261-0A BRPI0906261A BRPI0906261A2 BR PI0906261 A2 BRPI0906261 A2 BR PI0906261A2 BR PI0906261 A BRPI0906261 A BR PI0906261A BR PI0906261 A2 BRPI0906261 A2 BR PI0906261A2
Authority
BR
Brazil
Prior art keywords
patient sample
asthma subtype
diagnosing
methods
therapeutic agent
Prior art date
Application number
BRPI0906261-0A
Other languages
English (en)
Inventor
Joseph R Arron
Barmak Modrek
John V Fahy
Prescott Woodruff
Original Assignee
Genentech Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40695508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0906261(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Univ California filed Critical Genentech Inc
Publication of BRPI0906261A2 publication Critical patent/BRPI0906261A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0906261-0A 2008-03-31 2009-03-31 "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" BRPI0906261A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7257208P 2008-03-31 2008-03-31
US4148008P 2008-04-01 2008-04-01
US12838308P 2008-05-20 2008-05-20
US20539209P 2009-01-16 2009-01-16
PCT/US2009/039033 WO2009124090A1 (en) 2008-03-31 2009-03-31 Compositions and methods for treating and diagnosing asthma

Publications (1)

Publication Number Publication Date
BRPI0906261A2 true BRPI0906261A2 (pt) 2015-07-07

Family

ID=40695508

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906261-0A BRPI0906261A2 (pt) 2008-03-31 2009-03-31 "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"

Country Status (15)

Country Link
US (1) US20110123530A1 (pt)
EP (2) EP2271770B1 (pt)
JP (3) JP6161233B2 (pt)
KR (2) KR102070761B1 (pt)
CN (2) CN112481367A (pt)
AU (1) AU2009231733B2 (pt)
BR (1) BRPI0906261A2 (pt)
CA (1) CA2718120A1 (pt)
IL (1) IL208366A0 (pt)
MX (1) MX348362B (pt)
NZ (2) NZ601815A (pt)
PH (1) PH12018500045A1 (pt)
RU (2) RU2607569C2 (pt)
SG (1) SG2014014138A (pt)
WO (1) WO2009124090A1 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
WO2010136481A1 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Il-13 binding protein
KR101135173B1 (ko) 2010-01-19 2012-04-16 한국생명공학연구원 Sh3rf2 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물
KR101180879B1 (ko) 2010-06-21 2012-09-07 중앙대학교 산학협력단 천식 진단용 유전자 마커 및 이를 이용한 천식 진단에 필요한 정보를 제공하는 방법
KR101366612B1 (ko) 2010-10-12 2014-02-25 한국생명공학연구원 시스타틴 c를 유효성분으로 함유하는 천식 예방 및 치료용 조성물
JP6005657B2 (ja) * 2010-12-16 2016-10-12 ジェネンテック, インコーポレイテッド Th2阻害に関連する診断及び治療
AU2013204894B2 (en) * 2010-12-16 2016-11-10 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
AU2012272559C1 (en) 2011-06-23 2017-04-20 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
US9732151B2 (en) * 2011-11-03 2017-08-15 Merck Sharp & Dohme Corp. Biomarkers for TSLP treatment
WO2013104103A1 (zh) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 诊断和预示肠癌的标志物
CN104334744A (zh) * 2012-03-27 2015-02-04 弗·哈夫曼-拉罗切有限公司 预测、诊断和治疗特发性肺纤维化的方法
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
EP2708898A1 (de) 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
WO2014059178A1 (en) * 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
SI2922875T1 (sl) 2012-11-20 2017-06-30 Sanofi Protitelesa anti-CEACAM5 in njihove uporabe
EP2931920B1 (en) * 2012-12-14 2018-03-07 The University of Newcastle Biomarkers of asthma inflammatory phenotypes and response to therapy
KR20150127591A (ko) * 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
WO2015009996A1 (en) * 2013-07-19 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treating eosinophilic esophagitis
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
US20160304866A1 (en) * 2013-09-27 2016-10-20 Aqua Therapeutics Co., Ltd. Drug for Disease Caused by Expression of Periostin Except Eye Disease, and Use Thereof
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
EP3099323A4 (en) 2014-01-27 2017-10-04 Medlmmune, LLC Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
MX2016009490A (es) 2014-02-07 2017-05-12 Medimmune Llc Ensayo novedoso para detectar periostina humana.
WO2015126750A1 (en) * 2014-02-19 2015-08-27 Array Biopharma Inc. BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO TREATMENT WITH A CRTh2 INHIBITOR
CN106029693A (zh) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
EP3218515B1 (en) * 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
US10351630B2 (en) 2015-01-09 2019-07-16 Medimmune, Llc Assay to detect human DPP-4
CA2977285A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
PT3347377T (pt) 2015-09-09 2021-04-30 Novartis Ag Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2017077391A2 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
JP6531629B2 (ja) * 2015-11-17 2019-06-19 株式会社ダイフク 物品搬送設備
EP4059570A1 (en) 2016-01-13 2022-09-21 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
EP3417079A4 (en) * 2016-02-17 2019-07-10 Icahn School of Medicine at Mount Sinai NASAL BIOMARKERS FOR ASTHMA
US20190064185A1 (en) * 2016-02-26 2019-02-28 National Jewish Health Methods of detecting and treating airway inflammatory diseases
PE20181952A1 (es) 2016-04-27 2018-12-17 Pfizer Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
KR101967826B1 (ko) * 2017-06-30 2019-04-11 아주대학교산학협력단 페리오스틴을 이용한 아이소사이아네이트 직업성 천식의 진단방법
ES2697299B2 (es) * 2017-07-19 2020-04-15 Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz Biomarcadores diferenciales de asma
ES2753602R1 (es) * 2017-07-19 2020-05-20 Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz Biomarcadores diferenciales de asma
CN109161590B (zh) * 2017-08-23 2022-03-18 中南大学 整合素β4基因DNA甲基化位点在制备哮喘和或COPD早期诊断的生物标志物的应用
CN107643405B (zh) * 2017-09-19 2020-07-17 上海市肺科医院 一种基于自身抗体检测的肺癌诊断试剂盒及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
WO2019204580A1 (en) 2018-04-20 2019-10-24 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
WO2020007227A1 (zh) * 2018-07-03 2020-01-09 首都医科大学附属北京同仁医院 检测慢性鼻窦炎伴鼻息肉亚型的方法和试剂盒及alox15基因作为生物标志物的应用
CN108913764A (zh) * 2018-07-03 2018-11-30 张罗 检测鼻腔脱落细胞中alox15基因表达量的方法及应用
CN108977511A (zh) * 2018-07-03 2018-12-11 张罗 检测鼻腔脱落细胞中cst1基因表达量的方法及应用
EP3599285A1 (en) * 2018-07-25 2020-01-29 Rheinische Friedrich-Wilhelms-Universität Bonn Method of diagnosing asthma subtypes
CN109439744A (zh) * 2018-12-24 2019-03-08 常州市第二人民医院 重症哮喘诊断用分子标志物
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
WO2020176700A1 (en) * 2019-02-27 2020-09-03 Yale University Compositions and methods for enhancing mucosal immunity
CN110672858A (zh) * 2019-10-18 2020-01-10 郑湘榕 一种检测试剂盒在制备用于婴幼儿喘息性疾病的检测试剂盒中的应用
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
TWI896700B (zh) * 2020-07-10 2025-09-11 大陸商上海濟煜醫藥科技有限公司 一種抗IgE的工程化抗體及其應用
JP2022061491A (ja) * 2020-10-06 2022-04-18 国立大学法人福井大学 慢性副鼻腔炎の患者を分類するためのデータの取得方法、およびその利用
IL302731A (en) 2020-11-10 2023-07-01 Sanofi Sa Formulation of an antibody-drug conjugate for CEACAM5
EP4636780A1 (en) 2022-12-16 2025-10-22 Yamaguchi University Asthmatic disease condition estimation server, asthmatic disease condition estimation program, and asthmatic disease condition estimation method
KR20250017928A (ko) * 2023-07-28 2025-02-04 재단법인 아산사회복지재단 객담 단백체를 이용한 생물학적 제제에 대한 천식 치료 반응성 예측을 위한 바이오마커 및 이의 용도
CN119464499A (zh) * 2024-12-16 2025-02-18 杭州泰合仁生物技术有限公司 Alox15作为肺腺癌的生物标志物及应用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578349A (en) * 1982-04-08 1986-03-25 Abbott Laboratories Immunoassay for carcinoembryonic antigen (CEA)
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6013772A (en) * 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
US5231009A (en) * 1986-08-13 1993-07-27 Molecular Diagnostics, Inc. Cdnas coding for members of the carcinoembryonic antigen family
US5122599A (en) * 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) * 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) * 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0604580A1 (en) * 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JPH05268982A (ja) * 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
ES2136664T3 (es) 1992-06-09 1999-12-01 Hoppe Ag Sistema de cierre y conjunto de cerradura.
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) * 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2175380A1 (en) * 1993-10-29 1995-05-04 Lan Bo Chen A novel tumor marker and novel method of isolating same
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996010911A1 (en) * 1994-10-05 1996-04-18 Immunex Corporation Cytokine designated lerk-6
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6911530B1 (en) * 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU744087B2 (en) * 1997-05-29 2002-02-14 Board Of Regents, The University Of Texas System OSF2/CBFA1 compositions and methods of use
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002513295A (ja) * 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 123種類のヒト分泌タンパク質
US6040498A (en) * 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) * 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6482403B1 (en) * 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) * 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU2750800A (en) * 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
DE60022369T2 (de) * 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
WO2001044463A1 (en) * 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7439064B2 (en) * 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1319408B1 (en) * 2000-09-08 2010-07-28 Daiichi Sankyo Company, Limited Remedies for heart failure
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) * 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1992643A3 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US20040002112A1 (en) * 2001-10-31 2004-01-01 Matthias Mann Proteins involved in regulation of adipocytes and uses related thereto
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN102911987B (zh) * 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US20040132140A1 (en) * 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4628679B2 (ja) * 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
WO2003084569A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1613273B1 (en) * 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
JP4703567B2 (ja) * 2003-05-23 2011-06-15 ジェネンテック, インコーポレイテッド 膠細胞起源の腫瘍の診断と治療のための組成物と方法
US7601505B2 (en) * 2003-05-29 2009-10-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005000098A2 (en) * 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
DK2805728T3 (da) * 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
KR100635540B1 (ko) * 2004-10-12 2006-10-18 경북대학교 산학협력단 신규한 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
US8017119B2 (en) * 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Il−4および/またはil−13に結合するリガンド
EP1987359B1 (en) * 2006-02-22 2015-03-18 Philogen S.p.A. Vascular tumor markers
EP2059533B1 (en) * 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
JP4369468B2 (ja) * 2006-12-15 2009-11-18 日本分光株式会社 不可逆反応測定方法
WO2008083695A1 (de) 2006-12-20 2008-07-17 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Vorrichtung und verfahren zur messung der intensität des lichtes einer ersten gruppe von lichtquellen einer beleuchtungseinheit
RU2500686C2 (ru) 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
US8138056B2 (en) * 2009-07-03 2012-03-20 International Business Machines Corporation Thermally insulated phase change material memory cells with pillar structure
JP6005657B2 (ja) * 2010-12-16 2016-10-12 ジェネンテック, インコーポレイテッド Th2阻害に関連する診断及び治療
CN106029693A (zh) * 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
EP3218515B1 (en) * 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders

Also Published As

Publication number Publication date
EP2631302A3 (en) 2014-01-08
JP2015166738A (ja) 2015-09-24
MX348362B (es) 2017-06-07
US20110123530A1 (en) 2011-05-26
KR20170063996A (ko) 2017-06-08
RU2607569C2 (ru) 2017-01-10
SG2014014138A (en) 2014-07-30
EP2271770A1 (en) 2011-01-12
KR20100131003A (ko) 2010-12-14
EP2271770B1 (en) 2018-08-22
NZ601815A (en) 2014-10-31
IL208366A0 (en) 2010-12-30
CN112481367A (zh) 2021-03-12
JP6161233B2 (ja) 2017-07-12
MX2010010746A (es) 2010-10-15
CN102232113A (zh) 2011-11-02
PH12018500045A1 (en) 2019-10-28
NZ588853A (en) 2013-07-26
JP2014204725A (ja) 2014-10-30
RU2014110413A (ru) 2015-09-27
RU2010144502A (ru) 2012-05-10
KR102070761B1 (ko) 2020-01-29
AU2009231733A1 (en) 2009-10-08
AU2009231733B2 (en) 2015-12-24
JP2011523350A (ja) 2011-08-11
EP2631302A2 (en) 2013-08-28
WO2009124090A1 (en) 2009-10-08
JP6037515B2 (ja) 2016-12-07
CA2718120A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0906261A2 (pt) "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
BRPI0906903A2 (pt) ''anticorpo kit de diagnóstico, método de detecção da expressão de cd70 em uma amostra de tecido, método para prognosticar, determinar um protocolo de tratamento ou monitorar o tratamento, uso de um agente de ligação a cd70 e combinação de um kit de diagnóstico e um kit farmacêutico
BRPI0907663A8 (pt) composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
EP2134855A4 (en) USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY
EP2076172A4 (en) USE OF COHERENT RAMAN PROCEDURES FOR MEDICAL DIAGNOSTIC AND THERAPEUTIC PURPOSES AND CALIBRATION METHOD THEREFOR
EP2200548A4 (en) FLUID FLOW DEVICE AND METHOD FOR DIAGNOSING OR THERAPY OF TISSUE
PL2294582T3 (pl) Urządzenie i sposób wytwarzania izotopów medycznych
BRPI0807927A2 (pt) Métodos para determinar uma susceptibilidade a doença cardiovascular em um indivíduo humano, de identificação de um marcador para uso para avaliar susceptibilidade a doença cardiovascular, para genotipar uma amostra de ácido nucleico, para avaliar um indivíduo para probabilidade de resposta a um agente terapêutico, para predizer prognóstico de um indivíduo diagnosticado com doença cardiovascular, e para monitorar progresso de tratamento de um indivíduo passando por tratamento para doença cardiovascular, kit para avaliar susceptibilidade a doença cardiovascular em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para doença cardiovascular em um indivíduo humano
HRP20190031T1 (hr) Sintetski triterpenoidi i postupci njihove upotrebe u liječenju bolesti
EP2040699A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC COX-2 TARGETING
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
DE602007010480D1 (de) Blutsensor und diesen enthaltendes blutuntersuchungsinstrument
EP2240077A4 (en) SYSTEM AND METHOD FOR COSMETIC ANALYSIS AND TREATMENT DIAGNOSIS
EP2300599A4 (en) INCREASING THE EFFECTIVENESS OF CELL THERAPY, INCLUDING TREATMENT WITH ALPHA-1-3-FUCOSYLTRANSFERASE
WO2009061800A3 (en) Methods and compositions for diagnostic use in cancer patients
GB0913043D0 (en) Method and device of detecting shape and bone strength diagnostic device using the device
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
BR112015013374A2 (pt) dispositivo de luva hemostática e método para uso do mesmo
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
SI2170877T1 (sl) Substutuirani (oksazolidinon-5-il-metil)-2-tiofen-karboksamidi in njihova uporaba na področju koagulacije krvi
EP1989216A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
BRPI0909563A2 (pt) biomaterial, método de produção do biomaterial, uso do biomaterial e mpetodo de tratamento de lesões de tecidos em pacientes
WO2010127057A3 (en) Biomarkers of therapeutic responsiveness
CL2007003484A1 (es) Composicion farmaceutica que comprende valsartan y un tensoactivo, un componente lipofilico y un componente hidrofilico; procedimiento de preparacion; y uso en el tratamiento de la insuficiencia cardiaca, angina, infarto de miocardio, arterioescleros
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements